Enzyme-catalysed oxygenation and deoxygenation routes to chiral thiosulfinates

Derek R. Boyd,^{*a} Narain D. Sharma,^a Martina A. Kennedy,^a Steven D. Shepherd,^a John F. Malone,^a André Alves-Areias,^a Robert Holt,^b Stig G. Allenmark,^c Malin A. Lemurell (*née* Andersson),^c Howard Dalton^d and Heather Luckarift^d

^a School of Chemistry, The Queen's University of Belfast, Belfast, UK BT9 5AG

^b Avecia Pharmaceuticals, Billingham, Cleveland, UK TS23 1YN

^c Department of Chemistry, University of Göteborg, SE-412 96 Göteborg, Sweden

^d Department of Biological Sciences, The University of Warwick, Coventry, UK CV4 7AL

Received (in Cambridge, UK) 28th March 2002, Accepted 15th May 2002 First published as an Advance Article on the web 6th June 2002

Enantioenriched thiosulfinates have been obtained by dioxygenase- and chloroperoxidase-catalysed oxidation of 1,2-disulfides and dimethyl sulfoxide reductase- catalysed deoxygenation.

The reduction of a 1,2-disulfide bond to the corresponding thiol group $(\mathbf{A} \rightarrow \mathbf{B})$, and the reverse oxidation process $(\mathbf{B} \rightarrow \mathbf{A})$ are common reactions in protein chemistry. By comparison, enzyme-catalysed monooxygenation of 1,2-disulfides (**A**) to yield isolable thiosulfinates (**C**) is uncommon while enzyme-catalysed deoxygenation of thiosulfinates ($\mathbf{C} \rightarrow \mathbf{A}$) is unprecedented (Scheme 1).

$$2R-SH \xrightarrow{+ [2H]} R-S \xrightarrow{S-R} \xrightarrow{Enz+[0]} R-S \xrightarrow{O} S-R$$
(B)
(A)
(C)

Scheme 1 Oxidation and reduction reactions of 1,2-disulfides.

The eucaryotic oxidation of naturally occurring 1,2-disulfides **A** (*e.g.* $R = CH_2C=CH_2$, and $n-Pr)^1$ to yield the corresponding thiosulfinates **C** using cytochrome P-450 and flavin-containing monooxygenases from human liver microsomes has recently been reported.² Prior to this study, only one report of a procaryotic enzyme-catalysed oxidation of 1,2-disulfides **A** to the corresponding thiosulfinates **C** has appeared.³ Thus, stereoselective sulfoxidation of symmetrical 1,2-disulfides **A** (R = n-Bu, i-Pr, t-Bu, 22–97% enantiomeric excess, ee), utilising cyclohexanone monooxygenase from the bacterium *Acinetobacter calcoaceticus* was observed.³

As toluene dioxygenase (TDO), naphthalene dioxygenase (NDO) and chloroperoxidase (CPO) enzymes are known to catalyse the stereoselective sulfoxidation of aryl alkyl sulfides,^{4–9} the focus of this study was to examine the potential of these enzymes to catalyse the asymmetric sulfoxidation of 1,2-disulfides (**A**) to yield the corresponding thiosulfinates (**C**). When methyl phenyl disulfide **1** was added to whole cell cultures of *Pseudomonas putida* UV4 (TDO), diphenyl disulfide **4** (28% yield) and (*R*)-methyl phenyl sulfoxide **7** (6–9% yield, 96% ee), rather than the anticipated thiosulfinate **5** (**R** = Me), were formed (Scheme 2). With whole cells of *P. putida* NCIMB 8859 (NDO) and substrate **1**, disulfide **4** (5% yield) and



scheme 2 1DO- or NDO-catalysed oxidation products from 1,2-disulfides.

(S) methyl phenyl sulfoxide 7 (11% yield, 94% ee) were isolated. Furthermore, when 1,2-sulfides 2, 3 and 4 were each added to P. putida UV4 or P. putida NCIMB 8859, diphenyl disulfide 4 (2–34% yield) and sulfoxide 7 (1–4% yield) of (R)and (S) configurations, respectively, were obtained. These results are consistent with an intracellular reductive cleavage of the S-S bond to yield the corresponding thiols. The less volatile benzene thiol was then converted to disulfide 4 or gave methyl phenyl sulfide 6 (after enzyme-catalysed methylation) and sulfoxide 7 (after dioxygenase-catalysed sulfoxidation of 6). Addition of benzene thiol as a substrate to P. putida UV4 also yielded disulfide 4 and (R)-sulfoxide 7. The dioxygenasecatalysed oxidation of methyl phenyl sulfide 1 had been found to give either the (R)- (>98% ee, TDO) or (S)- isomer (91% ee, NDO) enantiomer of sulfoxide 7.5,7 Chemically synthesised thiosulfinate 5 (R = Me) was unstable and thus unlikely to survive the biotransformation conditions.

1,4-Dihydrobenzo-2,3-dithian **8**, and the corresponding thiosulfinate **9** were adopted as model compounds due to their greater stabilities. As NDO had earlier been found to catalyse sulfoxidation of dialkyl sulfides,⁹ it was selected for the biotransformation of the cyclic 1,2-disulfide **8**; thiosulfinate **9** was the only metabolite isolated (11–23% yield, 10% excess of the *S* enantiomer by chiral stationary phase [CSP] HPLC analysis Whelk-O1 column, α 2.8, t-butyl methyl ether). Since thiosulfinate **9** had not been resolved or stereochemically assigned earlier, its enantiomers were separated by semipreparative CSP HPLC and (+)-enantiomer **9** ([α]_D +250 CHCl₃) was found to have an (*S*) configuration by an X-ray crystal structure analysis¹⁰ (Fig. 1).[†]

1,2-Disulfide **8**, as substrate to *P. putida* UV4, produced two unexpected metabolites; the less polar was identified as 2-thiophthalide **10** (17% yield) and the more polar as *cis*dihydrodiol **11** ($[\alpha]_D$ +169, CHCl₃, 3% yield). The structure and (4*R*,5*S*) absolute configuration of diol **11** was determined by NMR spectral methods and by X-ray crystallographic analysis of the hydrogenated derivative **12** ($[\alpha]_D$ +20, CHCl₃; CCDC 185045).† Possible metabolic pathways involving TDO-catalysed benzylic hydroxylation to yield hemithioacetal **13**, followed by reductive cleavage of the S–S bond and loss of H₂S to give aldehyde **14** (in equilibrium with the cyclic hemiacetal **15**) are shown in Scheme 3. Dehydrogenation of the hemiacetal



Fig. 1 X-Ray structure of the (S)-enantiomer of thiosulfinate 9.

DOI: 10.1039/b203139f



15 could account for the formation of 2-thiophthalide **10**. *cis*-Dihydrodiol **11** could be formed by a *cis*-dihydroxylation/ dehydration sequence *via* the triol intermediate **16** or a dehydration/*cis*-dihydroxylation sequence *via* benzo[*c*]thiophene **17**; addition of benzo[*c*]thiophene **17** as a substrate to *P*. *putida* UV4 gave *cis*-dihydrodiol **11** of identical (4*R*,5*S*) configuration. Since dioxygenase-catalysed benzylic monol \rightarrow triol \rightarrow diol metabolic pathways are precedented using *P*. *putida* UV4,¹¹ the biosynthetic sequence **15** \rightarrow **16** \rightarrow **11** is preferred.

CPO enzyme from Caldariomyces fumago, a biocatalyst for the synthesis of enantiopure sulfoxides from sulfide precursors,¹²⁻¹⁴ was applied to the asymmetric oxidation of 1,2-disulfides. The cyclic 1,2-disulfides 8 and 18 were selected as substrates for reaction with a suspension of CPO (Sigma) under previously reported conditions;^{13,14} 1,2-disulfide 8 was biotransformed into thiosulfinate 9 (ca: 60% yield) with an excess of the (S) configuration (32-47% ee). The more watersoluble monocyclic 1,2-disulfide 18 was a better substrate for CPO; it gave the corresponding (S) thiosulfinate 19 in essentially quantitative yield and in almost enantiopure form (96% ee by CSP HPLC). The enantiomers of thiosulfinate 19 were separated by semi-preparative CSP HPLC (Whelk-01 column, α 1.4, t-butylmethyl ether: hexane; 1:1). The absolute configuration of (-) enantiomer 19 ($[\alpha]_D$ -338, CHCl₃) was assigned as (R) by circular dichroism spectral correlation.

A new range of wild-type anaerobic bacterial strains was found to catalyse the stereoselective deoxygenation of sulfoxides. Using one of these strains (DMSO-11) of the bacterium *Citrobacter braakii* containing dimethyl sulfoxide reductase (DMSOR), enantiomeric enrichment *via* kinetic resolution of the racemic sulfoxide substrates was achieved. Thus, enriched samples of alkylaryl sulfoxides (*e.g.* sulfoxide **20** [>98% ee]), dialkyl sulfoxides (*e.g.* sulfoxide **21** [44% ee]) and cyclic sulfoxides (*e.g.* sulfoxide **22** [97% ee]) were obtained. When racemic thiosulfinate **9** was used as a substrate for the intact



Scheme 3 NDO- and TDO-catalysed oxidation products from 1,2-disulfide 8

cells of C. braakii DMSO-11, the residual samples of substrate 9. isolated after biotransformations, were consistently found to have an excess of the (S) enantiomer (17-77% ee). A timecourse experiment with partially purified DMSOR enzyme isolated from C. braakii DMSO-11, and racemic thiosulfinate 9 allowed both the 1,2-disulfide bioproduct 8, and the residual thiosulfinate 9 (95% ee, (S)), to be isolated (Scheme 3). Addition of racemic thiosulfinate 23 to whole cell cultures of C. braakii DMSO-11 showed some evidence of kinetic resolution (4% excess of the R configuration). Enantiomers of thiosulfinate 23 were separated by CSP HPLC using identical conditions to those used for thiosulfinate 19. The (+) enantiomer of thiosulfinate 23 ($[\alpha]_D$ +150, CHCl₃) was found to have an (*R*) configuration by comparison with the (-)-(S) enantiomer whose configuration was assigned by X-ray crystal structure analysis (CCDC 185046).†

In conclusion, the preliminary results contained herein indicate that stereoselective oxygenation of 1,2-disulfides (using NDO and CPO) and deoxygenation of racemic thiosulfinates (using DMSOR) can yield enantiomerically enriched thiosulfinates. In addition novel metabolic pathways for 1,2-disulfides and thiosulfinates have been found.

We thank the BBSRC and DTI for postdoctoral support under the Applied Biocatalysis LINK Programme (NDS and HL), the ESF (MAK) and DENI (SS) for postgraduate studentships, Dr O. Ishihara (Evotec OAI) and Dr G. Robinson (Astra-Zeneca) for helpful discussion, Dr J. Hamilton for GC/MS analysis data, and Dr R. Hamilton and Dr A. King for assistance with the synthesis of 1,2-disulfide and thiosulfinate substrates.

Notes and references

† See http://www.rsc.org/suppdata/cc/b2/b203139f/ for crystallographic files in .cif or other electronic format.

- E. Block, S. Ahmad, J. L. Catafalmo, M. K. Jain and R. Apitz-Castro, J. Am. Chem.Soc., 1986, 108, 7045.
- 2 C. Teyssier and M.-H. Siess, Drug. Metab. Dispos., 2000, 28, 648
- 3 S. Colonna, N. Gaggero, G. Carrea, P. Pasta, V. Alphand and R. Furstoss, *Chirality*, 2001, **13**, 40.
- 4 J. R. Cashman, L. D. Olsen, D. R. Boyd, R. A. S. McMordie, R. Dunlop and H. Dalton, J. Am. Chem. Soc., 1992, 114, 8772.
- 5 C. C. R. Allen, D. R. Boyd, H. Dalton, N. D. Sharma, S. A. Haughey, R. A. S. McMordie, B. T. McMurray, K. Sproule and G. N. Sheldrake, *J. Chem. Soc., Chem. Commun.*, 1995, 119.
- 6 K. Lee, J. M. Brand and D. T. Gibson, Biochem. Biophys. Res. Commun., 1995, 212, 9.
- 7 D. R. Boyd, N. D. Sharma, S. A. Haughey, M. A. Kennedy, B. T. McMurray, G. N. Sheldrake, C. C. R. Allen, H. Dalton and K. Sproule, J. Chem. Soc., Perkin Trans. 1, 1998, 1929.
- 8 A. Kerridge, A. Willetts and H. Holland, J. Mol. Catalysis B: Enzymatic, 1999, 6, 59.
- 9 D. R. Boyd, N. D. Sharma, S. A. Haughey, J. F. Malone, A. King, B. T. McMurray, R. Holt and H. Dalton, J. Chem. Soc., Perkin Trans. 1, 2001, 3288.
- 10 *Crystal data* for (+)-(*S*)-thiosulfinate **9**: C₈H₈OS₂, M = 184.3, monoclinic, space group $P2_1$, a = 7.712(1), b = 4.705(1), c = 11.636(2) Å, $\beta = 102.59(1)^\circ$, V = 412.1(1) Å³, Z = 2, $D_c = 1.485$ g cm⁻³, T = 300(2) K, F(000) = 192, P4 diffractometer, 1067 observed reflections (> 2 σ (*I*)), 101 parameters, R1 = 0.048, wR2 = 0.123 (all data), GoF = 1.08, *Flack* x = -0.06(5). CCDC 183077.
- 11 D. R. Boyd, N. D Sharma and C. C. R. Allen, Curr. Opin. Biotechnol., 2001, 12, 564.
- 12 S. Colonna, N. Gaggero, L. Casella, G. Carrea and P. Pasta, *Tetrahedron: Asymmetry*, 1992, **3**, 95.
- 13 S. Allenmark and M. Andersson, *Tetrahedron: Asymmetry*, 1996, 7, 1089.
- 14 S. Allenmark and M. Andersson, Chirality, 1998, 10, 264.